George Poste

Chf Scientist & Regent's Prof

Regents'' Professor, BI: Bioenergetics, Center for (BE)
Regents'' Professor, BI: Personalized Diagnostics, Virginia G. Piper Center for (PD)
Chief Scientist & Regents'' Professor, Knowledge Enterprise (KE)
Regents'' Professor, BI: Innovations in Medicine, Center for (IM)
Chief Scientist & Regents' Professor, Complex Adaptive Systems (CAS)
Regents'' Professor, CLAS-NS: Life Sciences, School of (SOLS)
Professor, BI: Immunotherapy, Vaccines and Virotherapy, Center for (CIVV)

13557 Citations
61 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Education/Academic qualification

DSc, University of Bristol

… → 1987

PHD, University of Bristol

… → 1969

DVM, University of Bristol

… → 1966

Fingerprint Dive into the research topics where George Poste is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

13557 Citations
61 h-Index
196 Article
32 Review article
9 Chapter
8 Comment/debate
10 More

Serving Individuals and Populations Within Integrated Health Systems: A Bridge Too Far?

Moses, H., Matheson, D. H. M. & Poste, G., Jan 1 2019, In : JAMA - Journal of the American Medical Association.

Research output: Contribution to journal › Comment/debate

Adaptive global innovative learning environment for glioblastoma: GBM AGILE

GBM AGILE Network, Feb 15 2018, In : Clinical Cancer Research. 24, 4, p. 737-743 7 p.

Research output: Contribution to journal › Review article

35 Scopus citations

Converging and emerging threats to health security

Raina Macintyre, C., Engells, T. E., Scotch, M., Heslop, D. J., Gumel, A., Poste, G., Chen, X., Herche, W., Steinhöfel, K., Lim, S. & Broom, A., Jun 1 2018, In : Environment Systems and Decisions. 38, 2, p. 198-207 10 p.

Research output: Contribution to journal › Review article

12 Scopus citations

Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets

Domenyuk, V., Liu, X., Magee, D., Gatalica, Z., Stark, A., Kennedy, P., Rosenow, M., Barker, A., Berry, D., Poste, G., Halbert, D., Hart, C., Famulok, M., Mayer, G., Korn, M., Miglarese, M. & Spetzler, D., Jun 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. v36

Research output: Contribution to journal › Article

Open Access

48 Scopus citations

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

Domenyuk, V., Gatalica, Z., Santhanam, R., Wei, X., Stark, A., Kennedy, P., Toussaint, B., Levenberg, S., Wang, J., Xiao, N., Greil, R., Rinnerthaler, G., Gampenrieder, S. P., Heimberger, A. B., Berry, D. A., Barker, A., Quackenbush, J., Marshall, J. L., Poste, G., Vacirca, J. L. & 9 others, Vidal, G. A., Schwartzberg, L. S., Halbert, D. D., Voss, A., Magee, D., Miglarese, M. R., Famulok, M., Mayer, G. & Spetzler, D., Dec 1 2018, In : Nature communications. 9, 1, 1219.

Research output: Contribution to journal › Article